|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2112166 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09007161.4 |
| Date of filing the European patent application | 1999-12-23 | |
| (97) | Date of publication of the European application | 2009-10-28 |
| (45) | Date of publication and mention of the grant of the patent | 2018-11-21 |
| (46) | Date of publication of the claims translation | 2019-03-12 |
| (30) | Number | Date | Country code |
| 113647 P | 1998-12-23 | US |
| (72) |
Hanson, Douglas Charles, US
Neveu, Mark Joseph, US
Mueller, Eileen Elliot, US
Hanke, Jeffrey Herbert, US
Gilman, Steven Christopher, US
Davis, C. Geoffrey, US
Corvalan, José Ramon, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
Amgen Fremont Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Žmogaus monokloniniai antikūnai prieš CTLA-4 |
| HUMAN MONOCLONAL ANTIBODIES TO CTLA-4 |
| Payment date | Validity (years) | Amount | |
| 2018-12-31 | 20 | 347.00 EUR |